Genelux Corp Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
Portfolio Pulse from Benzinga Newsdesk
Genelux Corporation (NASDAQ:GNLX) has announced positive results from a Phase 1 trial of intrapleural delivered Olvi-Vec in patients with malignant pleural effusion due to either MPM or metastatic disease. The results were published in Frontiers in Immunology.
July 10, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the Phase 1 trial of Genelux's Olvi-Vec could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that this is a Phase 1 trial, the impact may not be as significant as later-stage trials, but it still indicates progress in Genelux's product pipeline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100